Comprehensive molecular profiling, or biomarker testing, is the key to unlocking precision medicine. This crucial testing enables patients and their doctors to precisely target cancer by identifying therapies with potentially greater benefit, while ruling out drugs that are less likely to work and thus avoiding unnecessary toxicities and costs. Due to what we believe to be outdated medical coverage policies, however, many insurance providers limit coverage and access to comprehensive biomarker testing, which may increase cancer care disparities and negatively impact patient care.
Driven by an unwavering devotion to impact all cancer patients, Caris’ comprehensive molecular profiling leaves no stone unturned to help guide treatment decision and ongoing cancer care management. Propelled by a decade of innovation and relentless commitment to help build a better world, we are not waiting for change. We are the change – and it’s happening now.
We are working with lawmakers to improve access and insurance coverage for biomarker testing, as well as working with insurance providers to update medical coverage policies to ensure alignment with industry guidelines that reflect current standards of care and clinical practice for the benefit of cancer patients.
Significant evidence supporting gene profiling using sequencing panels that cover more than 50 genes continues to be published, including from the National Comprehensive Cancer Network® (NCCN), the American Society of Clinical Oncology (ASCO), and others:
Comprehensive Molecular Profiling Provides Value Across the Patient Journey
A comprehensive profiling approach enables oncologists to select the right therapy while avoiding costly non-beneficial therapies. In fact, more than 20 states have enacted, passed or introduced comprehensive biomarker testing bills to expand coverage and patient access in the U.S.4
of alterations are missed by small hotspot panels.5
of patients tested with non-NGS methods had a missed targeted therapy versus 3% of patients who underwent CMP.3
in overall total cost of care due to more optimal treatment in patients with lung cancer who received broad versus narrow panel testing.6
"*" indicates required fields
Biomarkers help oncologists make informed treatment decisions.
Knowing what cancer looks like at the molecular level can lead to better treatment options.
Check out our Video Library to learn more about Caris molecular profiling.
For questions about Caris molecular profiling please contact us.